Stephen Thorne

Company: KaliVir Immunotherapeutics

Job title: CSO

Seminars:

VET3-TGI, a TGF-Beta Targeting Clinical Oncolytic Virus Developed from the VET Platform for Systemic Delivery 10:00 am

KaliVir has developed the VET platform to develop oncolytic virus backbones capable of achieving systemic delivery to solid tumors VET3-TGI represents the lead internal product from this platform and is undergoing clinical translational development In addition to unique intravenous delivery capabilities, VET3-TGI targets TGF-beta within the tumor microenvironment Pre-clinical data with this OV have demonstrated…Read more

day: Day Two